OA05.03 Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC)

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2016.11.252
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Prognostic Value of Delta‑like Protein 3 Combined With Thyroid Transcription Factor‑1 in Small‑cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2019English

Preclinical Evaluation of a GFRA1 Targeted Antibody-Drug Conjugate in Breast Cancer

Oncotarget
Oncology
2018English

Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702)

Oncologist
Cancer ResearchMedicineOncology
2019English

Single‐Agent Paclitaxel in the Treatment of Advanced Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
1999English

Tumor Stroma–targeted Antibody-Drug Conjugate Triggers Localized Anticancer Drug Release

Journal of Clinical Investigation
Medicine
2018English

Commentary on “Gemcitabine: Single‐Agent and Combination Therapy in Non‐Small Cell Lung Cancer”

Oncologist
Cancer ResearchMedicineOncology
1999English

Single Agent Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer. Phase II Study

Research in Oncology
2007English

Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients With Small Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

Antibody Drug Conjugates (ADC) Charged With HDAC Inhibitor for Targeted Epigenetic Modulation

Chemical Science
Chemistry
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy